



## Welcome

Dear colleagues

The number of malignancies where immunotherapy has gained approval has rapidly grown and increasingly immunotherapy is being combined with other treatment modalities. Expectations for further progress in the treatment of cancer are high in view of the rapid advancement of science and development of new immunotherapeutic agents. While many physicians have gained experience with the use of immune checkpoint inhibitors, the need for a multidisciplinary network of experts as back up to advise on the diagnosis and treatment of immune-related side effects has become apparent. At the Comprehensive Cancer Center Zürich, such a network has been established ([link](#)).

We invite you to take part in the Third Zürich Immuno-Oncology Symposium organized by the Comprehensive Cancer Center Zürich where a panel of renowned national and international experts will provide you with an overview of the field.

Prof. Dr. Rolf Stahel  
Chair  
Comprehensive Cancer Center Zürich

Prof. Dr. Michael Weller  
Deputy Chair  
Comprehensive Cancer Center Zürich

## Program

- 09.15 h**     **Welcome**  
Chairs: Alessandra Curioni, Reinhard Dummer, Rolf Stahel, Michael Weller
- 09.30 h**     **Keynote address**  
**Engaging the T-cell for the treatment of hematologic malignancies** – Ralf Bargou  
**Discussion**
- 10.30 h**     **Break**
- 10.45 h**     **Clinical results, patient cases and future developments I**  
**Melanoma** – Reinhard Dummer  
**Lung cancer** – Rolf Stahel  
**Other thoracic malignancies** – Alessandra Curioni  
**Discussion**
- 12.15 h**     **Lunch**
- 13.00 h**     **Clinical results, patient cases and future developments II**  
**CNS tumours** – Michael Weller  
**Head and neck cancer** – Kevin Harrington  
**Renal and bladder cancer** – Thomas Powles  
**Discussion**
- 14.30 h**     **Break**
- 14.45 h**     **Clinical results, patient cases and future developments III**  
**Hemato-Oncology** – Markus Manz  
**Breast tumours** – Giuseppe Curigliano  
**GI tumors** – Elizabeth Smyth  
**Discussion**
- 16.15 h**     **Developments in immunotherapy**  
**Developments in biomarkers and immune-oncology combinations** – Solange Peters  
**Discussion**
- 16.45 h**     **Wrap up and Apéro**